Aclaris Therapeutics, Inc. (ACRS) Social Stream
ACLARIS THERAPEUTICS INC (ACRS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ACRS.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-05-20 | 4 | $50 | $26 | $34 | $1.28 | 2556.25% |
| 2022-08-01 | 5 | $50 | $26 | $34.8 | $1.28 | 2618.75% |
| 2022-08-08 | 6 | $50 | $26 | $34.8 | $1.28 | 2618.75% |
| 2022-10-06 | 6 | $50 | $26 | $34.333 | $1.28 | 2582.27% |
| 2022-11-09 | 7 | $50 | $26 | $34.333 | $1.28 | 2582.27% |
| 2022-12-01 | 9 | $50 | $25 | $33 | $1.28 | 2478.12% |
| 2023-02-24 | 9 | $50 | $25 | $32.875 | $1.28 | 2468.36% |
| 2023-03-01 | 9 | $50 | $25 | $33.5 | $1.28 | 2517.19% |
| 2023-03-07 | 9 | $43 | $11 | $30 | $1.28 | 2243.75% |
| 2023-05-08 | 9 | $43 | $11 | $29.125 | $1.28 | 2175.39% |
| 2023-08-08 | 9 | $43 | $16 | $29.375 | $1.28 | 2194.92% |
| 2023-09-19 | 9 | $43 | $20 | $29.875 | $1.28 | 2233.98% |
| 2023-11-07 | 10 | $43 | $20 | $29 | $1.28 | 2165.62% |
| 2023-11-13 | 10 | $43 | $20 | $29 | $1.28 | 2165.62% |
| 2023-11-14 | 9 | $21 | $1 | $6 | $1.28 | 368.75% |
| 2023-12-18 | 10 | $21 | $1 | $5.937 | $1.28 | 363.83% |
The Trend in the Analyst Price Target
Over the past 20 months, ACRS's average price target has gone down $29.11.
ACRS reports an average of 695.65% for its upside potential over the past 45 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-01 | 9 | 50 | 25 | 33.500 | 12.240 | 173.69% |
| 2023-05-10 | 9 | 43 | 16 | 29.375 | 8.290 | 254.34% |
| 2023-11-07 | 10 | 43 | 20 | 29.000 | 5.420 | 435.06% |
| 2023-11-14 | 10 | 29 | 1 | 11.000 | 0.680 | 1517.65% |
| 2023-12-18 | 10 | 19 | 1 | 5.687 | 0.938 | 506.29% |
ACRS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2 | 5 | 0 | 5 | 0 | 0 | 10 |
The Trend in the Broker Recommendations
Over the past 31 weeks, ACRS's average broker recommendation rating worsened by 1.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- ACRS has a greater upside potential (average analyst target price relative to current price) than 2145.6% of all US stocks.
- ACLARIS THERAPEUTICS INC's number of analysts covering the stock is greater than 1891.77% of stocks in the small market cap category.
- ACRS has a lower variance in analysts' estimates than -1698.45% of stocks in the small market cap category.
- In terms of how ACLARIS THERAPEUTICS INC fares relative to stocks in the small market cap category, note that its average analyst price target is greater than 1327.2% of that group.
In the Pharmaceutical Products industry, ALPN, IMMP, and PRQR are the three stocks most similar to ACLARIS THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is ACRS a Buy, Hold or Sell? See the POWR Ratings now!